ArticleThe Journal of clinical endocrinology and metabolism2024
Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.
Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial.The Journal of clinical endocrinology and metabolism · 2025Trial
- Osteoporosis in Pediatric Orthopaedics: Congenital Diseases, Medical Management, and Perioperative Considerations.Current osteoporosis reports · 2026Review
- Bletilla striata polysaccharide inhibits osteoclast differentiation by suppressing macrophage glycolysis and MMP9 expression.In vitro cellular & developmental biology. Animal · 2026Article
- Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis.Bone reports · 2026Article
- Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study.Frontiers in endocrinology · 2026Article
- Craniofacial fibrous dysplasia: Molecular insights, long-term institutional experience, and evolving surgical strategies.Surgical neurology international · 2026Article
- Significant Response to Denosumab Yet with Severe Rebound Hypercalcemia in a 9-Year-Old Boy with Aneurysmal Bone Cyst: A Case Report.Children (Basel, Switzerland) · 2025Article
- Bisphosphonate therapy in pediatric fibrous dysplasia: A systematic review of clinical, biochemical, and radiological outcomes.Journal of clinical orthopaedics and trauma · 2025Article
- Clinical, Biochemical and Radiological Features of LRP5 Gene Variants in Children.Calcified tissue international · 2025Article
- Insights into Natural History, Phenotypic, and Molecular Spectrum in a Large Cohort of Osteosclerotic Disorders.Calcified tissue international · 2025Article
- Bone Health in Paediatric Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2025Review
- EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology.Hormone research in paediatrics · 2025Review
- Pediatric Fibrous Dysplasia of the Skull Base: Update on Management and Treatment.Brain sciences · 2024Review
- THE USE OF ORAL BISPHOSPHONATES IN REFRACTORY SEVERE HYPERCALCEMIA AFTER DENOSUMAB CESSATION.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 6 countries.
Funding
Abstract
contextDenosumab is an effective treatment for many receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated disorders but there are potential safety considerations and limited data to guide its use in children and adolescents.
objectiveThis document seeks to summarize the evidence and provide expert opinion on safe and appropriate use of denosumab in pediatric RANKL-mediated disorders.
participantsTen experts in pediatric bone and mineral medicine from 6 countries with experience in the use of denosumab participated in the creation of this document. EVIDENCE: Data were sourced from the published literature, primarily consisting of case reports/series and review articles because of the lack of higher level evidence. Expert opinion of the authors was used substantially when no published data were available.
conclusionDenosumab is an effective treatment for RANKL-mediated disorders in children and adolescents but is often not curative and, in some cases, is best used in conjunction with surgical or other medical treatments. Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimize risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.